효소면역측정법 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 검체별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Enzyme Immunoassay Market Size, Share & Trends Analysis Report By Product (Reagents & Kits, Software & Services), By Application (Oncology, Cardiology), By Specimen, By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,374,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,782,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,597,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

효소면역측정법 시장 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 효소면역측정법 시장 규모는 2024-2030년 CAGR 3.9%로 확대하며, 2030년에는 224억 2,000만 달러에 달할 것으로 예측되고 있습니다.

만성질환 및 감염성 질환의 유행, 현장 검사에 대한 수요 증가, 인식 및 의료비 지출 증가는 시장을 더욱 촉진할 것으로 예상됩니다. 또한 시장 진출기업 간의 합작 투자 및 제품 출시 증가, 정부 투자 증가도 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다. 예를 들어 2023년 7월 Anbio Biotechnology Limited는 POC(Point-Of-Care) 면역 진단을 위한 휴대용 솔루션인 AF-100S FIA 솔루션(AF-100S FIA Solution)을 출시했습니다. 이 분석기는 다양한 분석 대상 효소를 검출할 수 있으며, 시간당 최대 240건의 검사를 수행할 수 있습니다.

정부 투자 증가는 효소 면역 측정 기술 시장 성장을 크게 지원할 것으로 예상됩니다. 정부 투자는 주로 개발도상국의 의료 인프라 확충에 도움이 될 것입니다. 이러한 확대는 임상 현장에서 EIA 기술의 광범위한 채택과 통합을 돕고 질병의 조기 발견, 모니터링 및 관리 능력을 강화하는 데 도움이 될 것입니다. 또한 감염병 대응 및 예방 프로그램 등 대규모 검진 및 감시 활동에 EIA를 활용할 수 있는 국가 보건 프로그램의 수립을 촉진할 수 있습니다. 예를 들어 영국 정부는 2022년 3월 연구개발과 새로운 기기 및 진단약 생산을 강화하기 위해 3억 4,700만 달러를 투자할 것이라고 발표했습니다.

COVID-19 팬데믹은 시장에 큰 영향을 미쳤습니다. 전염병은 EIA 키트 및 시약을 포함한 다양한 헬스케어 제품공급망과 제조 공정에 장애를 일으켰습니다. 이러한 혼란은 봉쇄 조치, 인력 부족 및 물류 문제로 인해 발생했습니다. 그러나 COVID-19는 SARS-CoV-2 항체 검출을 위한 EIA 기술의 개발 및 채택을 가속화하여 시장에 영향을 미쳤습니다. 이러한 수요 급증의 배경에는 감염자를 식별하고 바이러스 확산을 파악하기 위한 대량 검사의 필요성이 있었습니다. 높은 특이성과 민감도로 알려진 효소 면역 측정법은 전염병 퇴치에 필수적인 툴이 되었으며, 활동성 감염을 진단하고 집단내 바이러스 확산 정도를 평가하는 연구에 사용되었습니다.

EIA의 개발과 최적화는 기술의 생물학적 측면과 공학적 측면 모두에서 상당한 전문성을 필요로 합니다. 높은 특이성과 민감도를 확보하는 것은 특히 새로운 표적이나 빠르게 변이하는 표적의 경우 어려운 과제입니다. 새로운 분석에 대한 규제 당국의 승인을 받는 데는 많은 시간과 비용이 소요됩니다. 규제 기준은 지역마다 크게 다르기 때문에 이러한 분석의 전 세계 유통과 활용을 복잡하게 만듭니다.

효소면역측정법 시장 보고서 하이라이트

• 제품별로는 시약 및 키트 분야가 2023년 67.5%의 점유율로 시장을 장악했습니다. 성장의 배경에는 감염성 및 자가면역질환의 유병률 증가가 있습니다.
• 용도별로는 감염성 질환 분야가 2023년 시장을 장악하고 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 검체별로는 혈액 검체 부문이 2023년 시장을 장악했습니다. 소변 검체 부문은 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
• 최종 용도별로는 병원 부문이 2023년 시장을 장악했습니다.
• 높은 구매력 평가, 양질의 의료 서비스에 대한 정부 지원, 상환 가능성과 같은 요인으로 인해 2023년 효소 면역 측정법 시장은 북미가 지배적이었습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/보조 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
• 업계 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 효소면역측정법 시장 : 제품 비즈니스 분석

• 부문 대시보드
• 세계의 효소면역측정법 시장의 제품 변동 분석
• 세계의 효소면역측정법 시장 규모와 동향 분석, 제품별, 2018-2030년
• 시약과 키트
• 분석기/계측 기기
• 소프트웨어와 서비스

제5장 효소면역측정법 시장 : 용도 비즈니스 분석

• 부문 대시보드
• 세계의 효소면역측정법 시장의 용도, 변동 분석
• 세계의 효소면역측정법 시장 규모와 동향 분석, 용도별, 2018-2030년
• 치료제 모니터링
• 종양학
• 심장병학
• 내분비학
• 감염증 검사
• 자가면역질환
• 기타

제6장 효소면역측정법 시장 : 검체 비즈니스 분석

• 부문 대시보드
• 세계의 효소면역측정법 시장의 검체 변동 분석
• 세계의 효소면역측정법 시장 규모와 동향 분석, 검체별, 2018-2030년
• 혈액
• 타액
• 뇨
• 기타 검체

제7장 효소면역측정법 시장 : 최종 용도 비즈니스 분석

• 부문 대시보드
• 세계의 효소면역측정법 시장의 최종 용도 변동 분석
• 세계의 효소면역측정법 시장 규모와 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 혈액은행
• 임상 검사실
• 제약·바이오테크놀러지 기업
• 학술연구 센터
• 기타

제8장 효소면역측정법 시장 : 제품, 용도, 검체, 최종 용도별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 및 동향 분석, 2018-2030년
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 구도

• 참여 기업
• 전략 매핑
• 기업 시장 현황 분석, 2023년
• 참여 기업의 개요
  • Siemens Healthineers
  • Danaher Corporation(Beckman Coulter)
  • bioMerieux SA
  • Sysmex Corporation
  • QuidelOrtho Corporation.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Becton, Dickinson, and Company
  • Thermo Fisher Scientific, Inc.

KSA

영문 목차

영문목차

Enzyme Immunoassay Market Growth & Trends:

The global enzyme immunoassay market size is anticipated to reach USD 22.42 billion by 2030, expanding at a CAGR of 3.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of chronic and infectious diseases, rising demand for point-of-care testing, and growing awareness and healthcare expenditure are expected to boost the market further. Moreover, the increasing number of joint ventures, product launches amongst market players and rising government investment is also expected to have a positive impact on market growth. For instance, in July 2023, Anbio Biotechnology Limited launched the AF-100S FIA Solution, a handheld solution for point-of-care immunodiagnostics. This analyzer can detect a broad spectrum of analyte enzymes and perform up to 240 tests per hour.

Rising government investment is expected to significantly support the market growth of enzyme immunoassay technologies. Government investments aid in the expansion of healthcare infrastructure, primarily in developing countries. This expansion helps in the wider adoption and integration of EIA technologies in clinical settings, enhancing the capacity for early disease detection, monitoring, and management. It also facilitates the establishment of national health programs that can use EIAs for large-scale screening and surveillance activities, such as infectious disease control and prevention programs. For instance, in March 2022, the UK government announced an investment of USD 347 million to enhance research and development and the production of novel devices and diagnostics.

The COVID-19 pandemic had a significant impact on the market. The pandemic caused disturbances in the supply chain and manufacturing processes of various healthcare products, including EIA kits and reagents. These disruptions were due to lockdown measures, labor shortages, and logistical challenges. However, the pandemic impacted the market by accelerating the development and adoption of EIA technologies for the detection of SARS-CoV-2 antibodies. This surge in demand was driven by the need for mass testing to identify infected individuals and understand the spread of the virus. Enzyme immunoassays, known for their specificity and sensitivity, became vital tools in the fight against the pandemic, used for diagnosing active infections and studies to assess the extent of virus spread within populations.

The development and optimization of EIAs require significant expertise in both the biological and engineering aspects of the technology. Ensuring high specificity and sensitivity can be challenging, especially for novel or rapidly mutating targets. Obtaining regulatory approval for new assays is a lengthy and expensive process. Regulatory standards can vary significantly between different regions, complicating the global distribution and use of these assays.

Enzyme Immunoassay Market Report Highlights:

• Based on product, the reagents and kits segment dominated the market with a share of 67.5% in 2023. The growth is attributed to the rising prevalence of infectious and autoimmune diseases
• Based on application, the infectious diseases segment dominated the market in 2023 and is expected to grow at the fastest CAGR over the forecast period
• Based on specimen, the blood specimen segment dominated the market in 2023. The urine specimen segment is anticipated to grow at the fastest CAGR over the forecast period
• Based on end-use, the hospitals segment dominated the market in 2023
• North America dominated the enzyme immunoassay market in 2023 owing to factors such as the high purchasing power parity, government support for quality healthcare, and availability of reimbursement

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Speicmen
  • 1.2.4. End-use
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising incidence of chronic and infectious diseases
    • 3.2.1.2. Increasing demand for point-of-care diagnostics
    • 3.2.1.3. Growing demand for portable and automated immunoassays
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lower detection limit
    • 3.2.2.2. Limitations associated with immunoassay techniques
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Enzyme Immunoassay Market: Product Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Enzyme Immunoassay Market Product Movement Analysis
• 4.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents & Kits
  • 4.4.1. Global Reagents & Kits Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Analyzers/Instruments
  • 4.5.1. Global Analyzers/Instruments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Software & Services
  • 4.6.1. Global Software & Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Enzyme Immunoassay Market: Application Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Enzyme Immunoassay Market Application, Movement Analysis
• 5.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Therapeutic Drug Monitoring
  • 5.4.1. Global Therapeutic Drug Monitoring Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Oncology
  • 5.5.1. Global Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cardiology
  • 5.6.1. Global Cardiology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Endocrinology
  • 5.7.1. Global Endocrinology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Infectious Disease Testing
  • 5.8.1. Global Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Autoimmune Diseases
  • 5.9.1. Global Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Enzyme Immunoassay Market: Specimen Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Enzyme Immunoassay Market Specimen Movement Analysis
• 6.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
• 6.4. Blood
  • 6.4.1. Global Blood Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Saliva
  • 6.5.1. Global Saliva Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Urine
  • 6.6.1. Global Urine Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Other Specimens
  • 6.7.1. Global Other Specimens Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Enzyme Immunoassay Market: End-use Business Analysis

• 7.1. Segment Dashboard
• 7.2. Global Enzyme Immunoassay Market End-use Movement Analysis
• 7.3. Global Enzyme Immunoassay Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Global Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Blood Banks
  • 7.5.1. Global Blood Banks Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Clinical Laboratories
  • 7.6.1. Global Clinical Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Pharmaceutical and Biotech Companies
  • 7.7.1. Global Pharmaceutical and Biotech Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Academic Research Centers
  • 7.8.1. Global Academic Research Centers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Global Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Enzyme Immunoassay Market: Regional Estimates & Trend Analysis by Product, Application, Specimen & End-use

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. North America Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Mexico
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Mexico Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. Argentina
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Argentina Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Enzyme Immunoassay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Participant's Overview
  • 9.4.1. Siemens Healthineers
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Danaher Corporation (Beckman Coulter)
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. bioMerieux SA
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Sysmex Corporation
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. QuidelOrtho Corporation.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Bio-Rad Laboratories, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. F. Hoffmann-La Roche AG
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Becton, Dickinson, and Company
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Thermo Fisher Scientific, Inc.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives

관련자료